Episode 3 of 3 - Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs
Tracking # 20-1042258
Free
There are no ratings for this course
Learn moreCourse overview
In the advent of novel targeted therapies for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), clinicians must consider the potential of adverse events (AEs) that can affect patient outcomes. In the last episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, our expert faculty will engage in an interactive discussion on AE-management to promote optimal treatment-decision making for clinicians. In addition, learn tips to on how to counsel your patients on monitoring their symptoms to support timely and effective care.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Medicine
Medical Doctor
Florida Board of Pharmacy
Pharmacist
Disclosure statements
FACULTY DISCLOSURES
Planner/Presenter
Sanjay Juneja, MD
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
Advisory Board/Consultant: Daiichi Sankyo and Guardant 360
Speakers’ Bureau: AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus
Stock Ownership: Phenomune and xCures
Independent Contractor: xCures
Planner/Presenter
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY
Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Janssen, and Pharmacyclics
Research Grant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Octapharma, Oncternal Therapeutics, MingSight, and TG Therapeutics
Planner/Presenter
Raajit K. Rampal, MD, PhD
Associate Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Advisory Board/Consultant for: AbbVie, Blueprint Medicines, Celgene/Bristol Myers Squibb, Constellation, CTI BioPharma, Disc Medicine, Galecto, Incyte, Novartis, Pharmaessentia, Promedior, Servier, Sierra Oncology/GlaxoSmithKline, Stemline, and Sumitomo Dainippon
Research Grant for: Constellation, Incyte, Ryvu, Stemline, Zentalis
Planner/Presenter
Christina Russomanno, MSN, RN, NP-C
Medical Oncology, Nurse Practitioner
Columbia University
Herbert Irving Comprehensive Cancer Center
New York, NY
Advisory Board/Consultant for: AbbVie,
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
SUPPORT STATMENT
Supported by educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.